Bristol-Myers Squibb Co (NYSE:BMY) Announces Quarterly Dividend of $0.45

Bristol-Myers Squibb Co (NYSE:BMY) announced a quarterly dividend on Thursday, June 11th, Zacks reports. Shareholders of record on Monday, July 6th will be given a dividend of 0.45 per share by the biopharmaceutical company on Monday, August 3rd. This represents a $1.80 annualized dividend and a yield of 3.11%. The ex-dividend date of this dividend is Thursday, July 2nd.

Bristol-Myers Squibb has raised its dividend payment by an average of 90.7% per year over the last three years and has increased its dividend every year for the last 10 years. Bristol-Myers Squibb has a payout ratio of 29.0% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Bristol-Myers Squibb to earn $7.35 per share next year, which means the company should continue to be able to cover its $1.80 annual dividend with an expected future payout ratio of 24.5%.

NYSE BMY opened at $57.80 on Tuesday. The company has a current ratio of 1.66, a quick ratio of 1.51 and a debt-to-equity ratio of 0.86. The firm’s fifty day moving average price is $59.82 and its two-hundred day moving average price is $60.91. Bristol-Myers Squibb has a 1 year low of $42.48 and a 1 year high of $68.34. The firm has a market capitalization of $130.20 billion, a P/E ratio of 71.36, a price-to-earnings-growth ratio of 1.11 and a beta of 0.73.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $1.72 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.49 by $0.23. The company had revenue of $10.78 billion for the quarter, compared to analyst estimates of $10.04 billion. Bristol-Myers Squibb had a net margin of 3.08% and a return on equity of 30.06%. The company’s revenue was up 82.1% on a year-over-year basis. During the same period in the prior year, the firm earned $1.10 earnings per share. On average, research analysts anticipate that Bristol-Myers Squibb will post 6.15 EPS for the current fiscal year.

In other Bristol-Myers Squibb news, SVP Adam Dubow sold 3,200 shares of the stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $61.01, for a total transaction of $195,232.00. Following the sale, the senior vice president now directly owns 16,086 shares in the company, valued at $981,406.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Dinesh C. Paliwal acquired 9,174 shares of Bristol-Myers Squibb stock in a transaction on Monday, June 15th. The shares were purchased at an average price of $54.50 per share, for a total transaction of $499,983.00. Following the completion of the purchase, the director now directly owns 22,109 shares of the company’s stock, valued at $1,204,940.50. The disclosure for this purchase can be found here. Corporate insiders own 0.14% of the company’s stock.

Several equities analysts have recently weighed in on the stock. Morgan Stanley raised shares of Bristol-Myers Squibb from an “equal weight” rating to an “overweight” rating and set a $64.00 price objective on the stock in a research report on Thursday, April 2nd. TheStreet lowered shares of Bristol-Myers Squibb from a “b-” rating to a “c+” rating in a research report on Monday, April 13th. William Blair reissued a “buy” rating on shares of Bristol-Myers Squibb in a research report on Monday, June 1st. Cfra increased their price objective on shares of Bristol-Myers Squibb from $69.00 to $70.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Finally, Societe Generale downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $50.00 price target on the stock. in a research note on Monday, March 23rd. One research analyst has rated the stock with a sell rating, four have issued a hold rating and eleven have assigned a buy rating to the company’s stock. Bristol-Myers Squibb currently has a consensus rating of “Buy” and an average price target of $68.00.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Featured Article: Risk Tolerance

Dividend History for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.